Kaiser Health News published an article today 5/15/20 entitled "Chasing the Elusive Dream of A Covid Cure. While the author, Liz Szabo discussed monoclonal antibodies as a possible therapy, NO MENTION of our candidate Leronlimab. In my first post two weeks ago I inquired if CYTODYN has a public relations agency with connections to East Coast media, specifically NYC. I received no response.As a novice investor I used a substantial portion of my savings to invest in CytoDyn because of its efficacy in Cancer treatment/cure. Now CytoDyn has doubled down on the drug's potential by throwing it's hat into the ring for a Coronavirus treatment. And yet, in the epicenter of the virus' virulence,my hometown, the drug's existence flies under the radar, I believe cream rises to the top and ultimately, the story that is Leronlimab will have its day in the court of medical and public opinion. But it seems it could use a push to climb the Nasdaq/ DJI ladder. Does RedChip Companies have sufficient contacts in the Media capital of the world to provide that push?